Quick Answer
UNITED THERAPEUTICS Corp reported R&D Expense of $550.00 million for fiscal year 2025.
UNITED THERAPEUTICS Corp R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $550.00M | +14.3% |
| 2024 | $481.00M | +17.9% |
| 2023 | $408.00M | +26.4% |
| 2022 | $322.90M | -40.2% |
| 2021 | $540.10M | +51.0% |
| 2020 | $357.70M | -69.8% |
| 2019 | $1.18B | +230.4% |
| 2018 | $357.90M | +35.3% |
| 2017 | $264.60M | +79.3% |
| 2016 | $147.60M | -39.8% |
| 2015 | $245.10M | +1.1% |
| 2014 | $242.50M | -19.0% |
| 2013 | $299.35M | +72.6% |
| 2012 | $173.39M | -3.7% |
| 2011 | $180.01M | +8.9% |
| 2010 | $165.31M | +37.3% |
| 2009 | $120.37M | -49.7% |
| 2008 | $239.18M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $127.50M | +23.2% | -4.9% |
| June 30, 2025 | $134.00M | -4.0% | -10.1% |
| March 31, 2025 | $149.00M | +43.1% | +44.0% |
| September 30, 2024 | $103.50M | +22.2% | -25.9% |
| June 30, 2024 | $139.60M | +56.9% | +34.1% |
| March 31, 2024 | $104.10M | +25.6% | +22.9% |
| September 30, 2023 | $84.70M | +28.1% | -4.8% |
| June 30, 2023 | $89.00M | -5.2% | +7.4% |
- UNITED THERAPEUTICS Corp showed an increase of +14.3% in R&D Expense compared to the prior fiscal year.
- Over the 2008–2025 period, UNITED THERAPEUTICS Corp’s r&d expense has grown by 130.0% (from $239.18 million to $550.00 million).
- The most recent figure is from UNITED THERAPEUTICS Corp’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: